Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL (RICER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01241734|
Recruitment Status : Unknown
Verified February 2014 by Hackensack Meridian Health.
Recruitment status was: Active, not recruiting
First Posted : November 16, 2010
Last Update Posted : February 4, 2014
The standard of care therapy for DLBCL in the relapsed setting is RICE with the plan for the patient to proceed to transplant. This protocol will add Revlimid to the first 7 days of the RICE therapy and again after transplant as maintenance. To improve over all outcome and survival.
Hypothesis is that combining lenalidomide with standard of care (RICE) may increase overall response rate thus increasing the number of patients able to proceed with autologous stem cell transplant. This in turn may translate into improved overall survival and progression free survival.
|Condition or disease||Intervention/treatment||Phase|
|Diffuse Large B-cell Lymphoma.||Drug: Revlimid||Phase 1 Phase 2|
This is a 3-Stage, phase I/II, single-arm, open-label study. The first and second stage of the study will assess the safety and efficacy of lenalidomide, rituximab, Ifosfamide, etoposide, and carboplatin (RICER) for the treatment of DLBCL patients in first relapse. The third stage of the study will assess the safety and efficacy of post-ASCT lenalidomide maintenance in patients with DLBC.
In stage I of the study, escalating doses of lenalidomide (10, 15, 20, and 25 mg daily x 7 days on Days 1-7) along with RICE therapy will be given to cohorts of subjects in a standard 3+3 design (see section 5.4.2 for dose escalation schema) until the maximum tolerated dose (MTD) has been determined.
In stage II, all subjects will be given RICE plus the MTD of lenalidomide. The starting dose of lenalidomide in Stage II will be modified for reduced renal function as outlined in Section 5.4.2.
In both stage I and stage II, subjects who have stable disease or progression of disease after 2 cycles of RICER will be taken off study. Subjects who achieve > PR to 2 cycles of RICER will receive a third cycle followed by stem cell collection and ASCT.
Each cycle is 14 days. Delays in initiating a new cycle are allowed up to 14 days for Stages I and II. The planned number of cycles is 3.
After the second cycle, restaging with PET and CT scans is performed. Patients with progressive disease are removed from the study, chemosensitive patients (CR/Cru and PR) proceed with third cycle of RICER. Stem cell collection will be completed within 10-14 days after third cycle of RICER. HDCMT-autoSCT will be performed after patient recovers from stem cell collection toxicities. HDCMT (high dose chemotherapy) followed by autologous stem cell transplant involves administration of chemotherapy with BEAM (BCNU, Etoposide, Ara-C, Melphalan) followed by infusion of autologous stem cells. Involved-field radiation to the sites of bulky disease will be allowed prior to HDCMT-SCT.
Stage III, after recovery from aSCT, but not to exceed 90 days all eligible subjects will receive lenalidomide maintenance therapy (po daily on Days 1-21 q28 days) for up to 1 year. Delays in initiating a new cycle up to 28 days are allowed in Stage III. Subjects will be followed for progression- free survival and overall survival for up to 2 years. The starting dose of lenalidomide maintenance treatment will be based on calculated creatinine clearance within 28 days prior to the start of lenalidomide maintenance
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||67 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)|
|Study Start Date :||June 2010|
|Estimated Primary Completion Date :||December 2014|
|Estimated Study Completion Date :||December 2014|
Experimental: Revlimid (Lenalidomide) in Combination
Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation
Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7
Lenalidomide 25mg days 1-21 every 28 days
Other Name: Lenalidomide
- Stage 1 - Safety (type, frequency, severity and relationship of adverse events to study treatment) and tolerability [ Time Frame: overall response rate ]compare the effect of treatment with 4 weeks of high dose IFN α-2b on the relapse free survival of patients with resected melanoma
- Stage 1 - Overall response rate (CR, PR, SD) [ Time Frame: overall response rate ]
- Stage 2 - Proportion of patients with a stem cell collection of at least 3x106 CD34+ cells prior to ASCT [ Time Frame: 1 and 2 Year Progression ]Stage 2 - 1 and 2 Year Progression Free Survival (PFS)
- Stage 3 - Overall response rate (CR, PR, SD) and complete response rate, and conversion to higher quality of response during maintenance (e.g. from PR to CR) [ Time Frame: Evaluate PFS at 2 yrs post transplant ]Evaluate PFS at 2 yrs post transplant
- Stage 2 • Incidence of DLT for determination of MTD to be used in Stage II conversion to higher quality of response during maintenance (e.g. from PR to CR) [ Time Frame: Response time ]Stage 2 - 1 and 2 Year Progression Free Survival (PFS)
- Time to Response [ Time Frame: 1 and 2 Year Progression Free Survival (PFS) ]Stage 2 - 1 and 2 Year Progression Free Survival (PFS)
- Stage 2 - 1 and 2 year Overall Survival (OS) [ Time Frame: Survival Time ]1 and 2 Year Progression Free Survival (PFS)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01241734
|United States, New Jersey|
|John Theurer Cancer Center at Hackensack University Medical Center|
|Hackensack, New Jersey, United States, 07601|
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27710|
|Principal Investigator:||Tatyana Feldman, MD||Hackensack Meridian Health|